Drug Safety Newsletter Issue 122: Hydroxycarbamide CGM Interference and Miconazole-Warfarin Interaction
Summary
The HPRA Drug Safety Newsletter Issue 122 (April 2026) covers four safety topics for medicines for human use: potential interference of hydroxycarbamide-containing products with continuous glucose monitoring systems; a drug-drug interaction between topical miconazole and warfarin; the importance of reporting suspected adverse reactions to pharmacovigilance; and updates from EMA's PRAC. The newsletter also references Direct Healthcare Professional Communications published on the HPRA website since the prior issue.
“The latest edition of the HPRA newsletter includes important updates to support the safe and appropriate use of the following medicines:”
What changed
The newsletter announces updated safety information on two specific drug interaction risks: hydroxycarbamide-containing products may interfere with continuous glucose monitoring system readings, and topical miconazole formulations can interact with warfarin therapy. These are communicated alongside broader pharmacovigilance reporting reminders and a summary of EMA PRAC product information updates.\n\nHealthcare providers and pharmaceutical companies should note these safety communications for incorporation into relevant prescribing and dispensing guidance. The HPRA's inclusion of DHPCs published since the last issue signals ongoing monitoring activity that affected parties should track on the HPRA website.
Archived snapshot
Apr 20, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HPRA Drug Safety Newsletter Issue 122 08 April 2026
08/04/2026 Medicines for human use Safety update
The latest edition of the HPRA newsletter includes important updates to support the safe and appropriate use of the following medicines:
Hydroxycarbamide-containing medicinal products: Potential interference with continuous glucose monitoring systems
Miconazole: Drug-drug interaction between miconazole topical formulations and warfarin
Reporting suspected adverse reactions: The importance of reports of suspected adverse reactions to pharmacovigilance
Product information updates recommended by the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC)
Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter
Documents
Drug Safety Newsletter Issue 122 April 2026 PDF : 232KB | 08/04/2026
Named provisions
Related changes
Get daily alerts for Ireland HPRA
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from HPRA Ireland.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Ireland HPRA publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.